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Abstract
The aim of the present study was to explore how mannose enters fibroblasts derived from a panel of children suffering
from different subtypes of type I carbohydrate deficient glycoprotein syndrome: seven carbohydrate deficient glycoprotein
syndrome subtype Ia (phosphomannomutase deficiency), two carbohydrate deficient glycoprotein syndrome subtype Ib
(phosphomannose isomerase deficiency) and two carbohydrate deficient glycoprotein syndrome subtype Ix (not identified
deficiency). We showed that a specific mannose transport system exists in all the cells tested but has different characteristics
with respect to carbohydrate deficient glycoprotein syndrome subtypes. Subtype Ia fibroblasts presented a mannose uptake
equivalent or higher (maximum 1.6-fold) than control cells with a D-[2-3H]-mannose incorporation in nascent N-
glycoproteins decreased up to 7-fold. Compared to control cells, the mannose uptake was greatly stimulated in subtype Ib
(4.0-fold), due to lower Kuptake and higher Vmax values. Subtype Ib cells showed an increased incorporation of D-[2-3H]-
mannose into nascent N-glycoproteins. Subtype Ix fibroblasts presented an intermediary status with mannose uptake
equivalent to the control but with an increased incorporation of D-[2-3H]-mannose in nascent N-glycoproteins. All together,
our results demonstrate quantitative and/or qualitative modifications in mannose transport of all carbohydrate deficient
glycoprotein syndrome fibroblasts in comparison to control cells, with a relative homogeneity within a considered subtype of
carbohydrate deficient glycoprotein syndrome. These results are consistent with the possible use of mannose as a therapeutic
agent in carbohydrate deficient glycoprotein syndrome Ib and Ix. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Type I carbohydrate de¢cient glycoprotein syn-
dromes (CDGS) are autosomal recessive multisyste-
mic disorders. Perturbation of the central and pe-
ripheral nervous system along with mental
retardation and hypotonia are predominant clinical
features, but many other organ systems are a¡ected
as well [1].
The characteristic feature of CDGS type I is ab-
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normal glycosylation of several serum glycoproteins
synthesized by the liver [2]. These glycoproteins have
a reduced number of glycan chains but the chains
that remain present are of the complex type and
correctly matured, indicating the glycosylation and
co-translational core glycosylation in the endoplas-
mic reticulum [3,4].
The molecular bases of type I CDGS are hetero-
genous, leading to di¡erent subtypes. At least two
enzymes show reduced or undetectable cellular activ-
ities which are related to gene mutations. 70^80% of
the type I CDGS are associated with an impaired
activity of phosphomannomutase (PMM) [5]. PMM
is responsible for the conversion of mannose 6-phos-
phate into the mannose 1-phosphate that is used for
the synthesis of GDP-mannose. This latter com-
pound is the donor of mannosyl residues needed
for the synthesis of the lipid-linked oligosaccharide
(LLO) in the endoplasmic reticulum. The mannose-
rich oligosaccharide is transferred en bloc onto nas-
cent proteins, after which the maturation process of
the N-linked glycoprotein glycan chains begins [6].
Two PMM genes have been located, on chromo-
somes 22 and 16 (PMM1 and PMM2 genes, respec-
tively). More than 10 missense mutations in the
PMM2 gene have been described [7]. Matthijs et al.
have proposed that the CDGS subtype Ia will be
called CDGS with PMM activity de¢ciency. Phos-
phomannose isomerase (PMI) which converts fruc-
tose 6-phosphate into mannose 6-phosphate is the
second newly implicated enzyme. The PMI activity
has been found to be reduced in ¢broblasts of some
CDGS patients without PMM de¢ciency [8,9]. This
new subtype with PMI de¢ciency has been termed Ib.
Other type I CDGS patients have defects in dehydro-
dolichol reductase [11] and glucosylation of dolichol
oligosaccharides [12,13]. In the present work CDGS
with neither PMM nor PMI de¢ciencies were classi-
¢ed as Ix.
Mannose is a central element in the N-glycoprotein
synthesis. Nevertheless, the origin of mannose incor-
porated in N-glycans is not yet clearly established. Its
interconversion from glucose and generation from N-
linked glycoproteins [14] and free high mannose oli-
gosaccharides [15,16] contribute to the formation of
an intracellular pool of mannose. It has recently been
shown in normal cells including ¢broblasts that ex-
tracellular mannose can be transported into the cells
by speci¢c transport systems [17^19]. Extracellular
mannose could participate to the intracellular pool
of mannose through the speci¢c transport system.
Mannose has been therefore proposed as a therapeu-
tic agent in type I CDGS [9]. However, to our
knowledge, there are only two reports concerning
mannose transport in CDGS cells, with only one or
two patients at a time [9,10].
Supplementation of the diet of patients with
CDGS type I with mannose may only provide ther-
apeutic bene¢ts if mannose can enter CDGS cells.
The aim of the present study was to explore the entry
of mannose into ¢broblasts derived from a panel of
patients with di¡erent CDGS subtypes. We show
that, despite alterations in kinetic parameters and
inhibitor pro¢les of mannose transport, CDGS cells,
whatever the subtype considered, were able to incor-
porate extracellular mannose.
2. Materials and methods
2.1. Materials
D-glucose, D-mannose, alpha-methyl-mannose
(AMM), phloretin, phloridzin and fructose were pur-
chased from Sigma (L’Isle d’Abeau, France). Dul-
becco’s modi¢ed essential medium (DMEM) and fe-
tal bovine serum (FBS) were obtained from Gibco
(Cergy-Pontoise, France).
D-[2-3H]-mannose (20 Ci/mmol) and [35S]-methio-
nine (14.3 mCi/ml) were obtained from Amersham
(Les Ulis, France). Soluene-350 and Pico-Fluor
were from Packard (Rungis, France). All other
chemicals were of analytical grade.
2.2. Cell populations
Fibroblasts were isolated from outgrowths of fore-
arm skin specimens from 11 patients diagnosed as
having type I CDGS based on clinical and biochem-
ical (glycoprotein Western blotting [20]) analysis.
PMM and PMI activities were measured as previ-
ously described [21]. Seven patients (A1^A7) were
type Ia (PMM de¢ciency), two others (B1, B2)
were classi¢ed as type Ib (PMI de¢ciency) and the
last two patients (X1, X2) were classi¢ed as Ix, (with-
out PMM or PMI de¢ciencies). Disease control ¢-
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broblasts were from pediatric patients with chromo-
somic abnormalities (other than on chromosomes 22
and 16).
Cells were serially passaged by trypsinization and
were used between the ¢fth and 15th passage. Fibro-
blasts were cultured to con£uency in DMEM con-
taining 2 mM glutamine, 100 U/ml pencillin, 100 Wg/
ml streptomycin and 10% (v/v) heat-inactivated FBS,
at 37‡C under 5% CO2.
2.3. Incorporation of [3H]-mannose into
glycoproteins
Fibroblasts in 12 well plates were washed twice
with glucose-free DMEM medium and labelled for
1 h with D-[2-3H]-mannose (20 WCi/ml) and [35S]-me-
thionine (2 WCi/ml) at 37‡C. After removal of the
radioactive medium, cells were washed three times
with 1 ml ice-cold phosphate-bu¡ered saline (PBS)
and submitted to TCA/TPA (10/1) precipitation
[22]. Cells were harvested by scraping and left over-
night at 4‡C. After centrifugation, the pellets were
washed with TCA/TPA and then solubilized in 500
Wl Soluene-350 at 60‡C for 30 min.
2.4. Measurement of [3H]-mannose uptake
Fibroblasts in 12 well plates were rinsed twice with
glucose-free DMEM and labelled for up to 15 min
with D-[2-3H]-mannose (20 or 40 WCi/ml) at 37‡C or
4‡C, to measure the mannose uptake. The e¡ects of
various competitors on the mannose uptake were
studied by including them in the labelling medium
at the concentrations indicated in the table legends.
The Kuptake and Vmax of mannose uptake were
measured by incubating the cells for 5 min at 37‡C
with 40 WCi/ml D-[2-3H]-mannose and varying the
amounts of unlabelled D-mannose (from 0 to 2500
WM). The total incorporated mannose is then pro-
portional to the speci¢c activity of mannose in the
labelling medium. After removal of the radioactive
medium, cells were washed three times in ice-cold
PBS and trypsinized. The radioactivity incorporated
in the cell pellets was counted and normalized to the
protein content.
Eadie-Hofstee plots indicated the existence of
more than one type of mannose transporter. The
Kuptake and Vmax for the two transport systems
were calculated using Lineweaver-Burk plots.
3. Results
3.1. Mannose incorporation into N-linked
glycoproteins derived from di¡erent subtype I
CDGS cells
The impairment of N-glycosylation in skin ¢bro-
Table 1
Mannose incorporation into nascent N-linked glycoproteins from di¡erent CDGS ¢broblasts
Cell population CDGS subtype Enzyme activitya (mU/mg protein) [3H]/[35S]b (% of the control)
PMM PMI
Control (n = 7) c 3.8 þ 0.5 43 þ 4.5 100
A1 Ia n.d. 33 þ 5.5 14
A2 Ia n.d. 37 þ 8.7 37
A3 Ia n.d. 33 þ 6.5 61
A4 Ia n.d. 55 þ 9.3 32
A5 Ia n.d. 43 þ 6.9 48
A6 Ia n.d. 37 þ 5.3 59
A7 Ia n.d. 111 þ 26 354
B1 Ib 3.9 n.d. 374
B2 Ib 8.9 n.d. 196
X1 Ix 2.0 60 þ 4.9 123
X2 Ix 5.7 34 þ 6 337
aEnzyme activities were measured in triplicate as previously described [21]. (n.d., not detectable).
bThe ratio [3H]/[35S] was measured in the TCA/TPA precipitable fraction after 60 min labelling with 20 WCi/ml D-[2-3H]-mannose and
2 WCi/ml [35S]-methionine as described in Section 2. Results are expressed as the percentage of control which is de¢ned as 100%.
BBADIS 61818 24-3-99
T. Dupre et al. / Biochimica et Biophysica Acta 1453 (1999) 369^377 371
Fig. 1. Kinetics of D-[2-3H]-mannose uptake in control and CDGS ¢broblasts. Fibroblasts were labelled with 20 WCi/ml D-[2-3H]-man-
nose in glucose-free DMEM for 15 min (upper panel) or from 0 to 60 s (lower panel). The D-[2-3H]-mannose incorporated into the
cellular compartment was determined as described in Section 2. Values are the mean þ S.D. of three independant experiments.
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blasts from patients su¡ering from di¡erent CDGS
subtypes is conveniently investigated after co-label-
ling with D-[2-3H]-mannose and [35S]-methionine fol-
lowed by TCA/PTA precipitation. The [3H]/[35S] ra-
tio in precipitates from subtype Ia CDGS ¢broblasts
was reduced with 1.7^7-fold in comparison with con-
trol cells (Table 1), in good agreement with previous
studies [10,22]. However in A7 ¢broblasts, from a
patient clinically and biochemically identi¢ed as hav-
ing CDGS Ia, the [3H]/[35S] ratio was 3.5-fold higher
than in control cells. In this patient, a metabolic
adaptation bypassing PMM de¢ciency is suggested
by Western blotting of serum glycoproteins (trans-
ferrin, haptoglobin, K1-anti-trypsin and orosomu-
coid) which were found to be identical to those
from healthy donors (data not shown).
In ¢broblasts from the two patients su¡ering from
CDGS type Ib, an increase in the [3H]/[35S] ratio was
observed (Table 1). This result is in line with a recent
report describing one case of CDGS type Ib [9]. We
found for the ¢rst time a [3H]/[35S] ratio increase in
CDGS type Ix ¢broblasts (Table 1).
Next we wanted to investigate whether or not var-
iations of the [3H]/[35S] ratio were related to modi¢-
cations in mannose uptake.
Mannose uptake in cultivated skin ¢broblasts
When cells were incubated for 15 min with D-
[2-3H]-mannose, the mannose uptake was greatly
stimulated in A7 ¢broblasts (3.0-fold) and CDGS
subtype Ib ¢broblasts (4.0-fold) when compared to
control cells and other CDGS ¢broblasts (Fig. 1,
upper panel). It is noteworthy that CDGS subtype
Ix ¢broblasts had a mannose uptake comparable to
control cells, whereas their [3H]/[35S] ratio was close
to that observed in subtype Ib CDGS ¢broblasts.
The in£uence of the intracellular mannose metab-
olism on its cell surface uptake cannot be excluded
during long periods of incubation (15 min). Since a
non-metabolizable radiolabelled analogue of man-
nose is not available, we performed kinetic studies
over short times (from 0 to 120 s). As shown in
Fig. 1, lower panel, variations observed after an in-
cubation period of 15 min were also present during
short incubations.
3.2. Mannose uptake is mainly due to speci¢c
facilitative transport in CDGS ¢broblasts
Whatever the cell population considered, the man-
nose uptake was strongly inhibited at 4‡C (Table 2).
This result demonstrated that mannose uptake was
the consequence of a transport mechanism in type I
CDGS ¢broblasts. Phloridzin, an inhibitor of the
Na-dependent glucose transporter family (SGLT1-
3) had a weak e¡ect on the mannose uptake with a
maximum inhibition of 20%. In contrast, mannose
uptake in control and type I CDGS ¢broblasts was
strongly inhibited by phloretin, a well known inhib-
itor of the facilitative hexose transporter (Table 2).
Glucose at 1 mM, a concentration 300-fold higher
Table 2
Characterization of mannose uptake into CDGS ¢broblasts
Cell population CDGS subtype Inhibition of mannose incorporation %
Temperature 4‡C Phloretin 100 WM Phloridzin 10 WM Glucose 1 mM Mannose 1 mM
Control c 95 67 9 30 66
A1 Ia 92 70 17 40 76
A2 Ia 90 71 12 36 81
A4 Ia 95 80 20 39 63
A5 Ia 91 70 16 15 38
A6 Ia 96 70 13 35 59
A7 Ia 93 66 9 54 44
B1 Ib 97 81 2 50 74
B2 Ib 93 74 9 38 47
X1 Ix 96 73 16 35 68
X2 Ix 96 69 11 29 59
Cells were labelled with 20 WCi/ml D-[2-3H]-mannose for 15 min in glucose-free DMEM. The incorporated radioactivity was counted
in the total lysate. Results are expressed as a percentage of inhibition of transport observed at 37‡C in the absence of competitor.
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than D-[2-3H]-mannose, only reduced the mannose
uptake with a mean of 38% in control and type I
CDGS ¢broblasts (range 15^54%). In contrast, 1
mM mannose was a more e⁄cient inhibitor than
glucose (V2.0-fold) of D-[2-3H]-mannose uptake in
control and all CDGS ¢broblasts except for the A7
cells (Table 2). From these results, we concluded
that, similarly to that observed in normal ¢broblasts,
mannose uptake was mediated by a speci¢c facilita-
tive transport in type I CDGS ¢broblasts.
3.3. Kinetic parameters of mannose transport
Eadie-Hofstee plots of mannose uptake in the
presence of D-[2-3H]-mannose and varying amounts
of unlabelled D-mannose present biphasic saturation
curves for type I CDGS and control ¢broblasts (data
not shown) suggesting the existence of two transport-
ers for mannose entry into cells, as previously re-
ported in normal human ¢broblasts [19]. One has a
high a⁄nity corresponding to a speci¢c facilitative
mannose transporter and the other one has a low
a⁄nity probably corresponding to Glut-1, the most
widely distributed isoform of the facilitative glucose
transporter.
We found Kuptake values in the range of 10^40 WM
and Vmax values, in the range of 10^45 pmol/Wg/min
for the high a⁄nity transporter. The CDGS ¢bro-
blasts without PMM de¢ciency (Ib and Ix) presented
a higher a⁄nity for mannose than control cells. Their
Kuptake values were 2.0^3.5-fold lower than the con-
trol (Table 3). In all populations of ¢broblasts de-
rived from subtype Ia CDGS patients, Kuptake values
were in the range of that of control cells. Similarly,
Vmax values in CDGS subtype Ia were close to that
obtained in control cells, except for A7 ¢broblasts
(1.7-fold the control). Vmax values were increased
1.4-fold in CDGS subtype Ib and decreased 2.1^
2.7-fold in CDGS subtype Ix as compared to control
cells.
A low a⁄nity mannose transport was detected in
Table 4
Comparison of mannose transport competitors in control and CDGS ¢broblasts
Cell population CDGS subtype Inhibition of mannose incorporation %
Talose 5 mM Mannoheptulose 5 mM AMM 5 mM dMM 1 mM
Control c 58 42 77 83
A1 Ia 49 14 38 10
A2 Ia 37 19 51 31
A4 Ia 53 21 43 14
A5 Ia 44 19 31 36
A6 Ia 39 16 52 17
A7 Ia 28 17 37 33
B1 Ib 52 37 37 52
B2 Ib 48 11 46 54
X1 Ix 43 12 33 18
X2 Ix 46 21 25 7
Cells were labelled with 20 WCi/ml D-[2-3H]-mannose for 15 min in glucose-free DMEM. The incorporated radioactivity was counted
in the total lysate. Results are expressed as a percentage of inhibition of transport observed at 37‡C in the absence of competitor.
Table 3
Kinetic parameters of the high a⁄nity mannose transporter in






Kuptake (WM) Vmax (pmol/mg/min)
Control c 34 27
A2 Ia 32 34
A4 Ia 39 29
A5 Ia 29 25
A7 Ia 27 44
B1 Ib 16 44
B2 Ib 20 39
X1 Ix 12 10
X2 Ix 16 13
Cells were labelled with 40 WCi/ml D-[2-3H]-mannose for 5 min
in glucose-free DMEM and in presence of varying amounts of
unlabelled mannose. The incorporated radioactivity was
counted in the total lysate. Based on the speci¢c activity of
D-[2-3H]-mannose in the medium, Kuptake and Vmax were calcu-
lated using Lineweaver-Burk plots.
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control (Kuptake = 1.1 mM, Vmax = 500 pmol/Wg/min)
and all CDGS ¢broblasts. Whatever the pathological
cells used, we observed a higher Kuptake (1.6^3.4-fold)
than in control cells. Vmax values were increased up
to 3-fold in all CDGS ¢broblasts except in A7 cells
(6-fold) when compared to control cells.
3.4. Pro¢le of mannose transport inhibition
Taking into account di¡erences in the kinetic pa-
rameters of mannose transport between control and
pathological cells, we analyzed the e¡ect of mono-
saccharides and mannose analogues on the mannose
uptake. We have previously shown that dMM, a
mannosidase inhibitor, is a potent inhibitor of man-
nose transport [18]. Among the inhibitors tested,
dMM and AMM were the most potent in control
¢broblasts. In contrast, pathological cells are less
sensitive to the inhibitory e¡ect of dMM and
AMM, a 3.1- and 2.0-fold reduction, respectively.
Talose (4-epimere of mannose) and mannoheptulose
(modi¢cation at the C1 position of mannose) are less
potent inhibitors than dMM and AMM in control
cells. However, mannose uptake inhibition by these
monosaccharides was more pronounced in control
than in pathological cells (Table 4).
4. Discussion
In this study, we have investigated the mannose
transport in a panel of well-de¢ned type I CDGS
¢broblasts: CDGS subtypes Ia, Ib and Ix. In each
case, we have identi¢ed a speci¢c and high a⁄nity
mannose transport system in addition to a low a⁄n-
ity transport. However, on the basis of inhibition
pro¢les, we have demonstrated that the detailed
mechanism of mannose transport is modi¢ed in
CDGS ¢broblasts, whatever the subtype considered,
as compared to control cells. Quantitative and/or
qualitative transport di¡erences were observed in ¢-
broblasts from patients with di¡erent CDGS sub-
types with relative homogeneity within a considered
subtype of CDGS.
First of all, we con¢rmed an alteration of mannose
incorporation into N-linked glycoproteins from the
¢broblasts of patients with di¡erent subtypes of
CDGS type I. In subtype Ia, we have shown a de-
crease in the D-[2-3H]-mannose incorporation into
nascent N-glycoproteins up to 7-fold. These results
are in good agreement with previous reports [10,22].
In an apparent discrepancy we found an enhanced
mannose incorporation into N-linked glycoproteins
in both subtypes Ib and Ix. Recently, similar results
have been described in one case of CDGS Ib [9]. The
authors evoked an increase of the labelled mannose
speci¢c activity due to the possible use of the intra-
cellular pool of mannose in the case of PMI de¢-
ciency but not in the case of PMM de¢ciency. Our
study is the ¢rst demonstration of such a phenomen-
on in subtype Ix. The discovery of the origin of the
defect in subtype Ix might help to elucidate the rea-
son to this increase of D-[2-3H]-mannose incorpora-
tion into nascent N-glycoproteins.
We report for the ¢rst time a well-de¢ned CDGS
subtype Ia patient (A7) with an atypic behavior in
regard to mannose uptake and mannose incorpora-
tion into nascent N-glycoproteins. The ¢broblasts of
this patient present a [3H]-mannose/[35S]-methionine
ratio and kinetic parameters of mannose uptake close
to those observed in CDGS subtype Ib ¢broblasts.
Further studies are underway in order to better de-
¢ne the mannose metabolism and glycoprotein syn-
thesis in these cells.
We demonstrated that although the basic mannose
transport characteristics are conserved in CDGS ¢-
broblasts in comparison to control cells, more de-
tailed experiments show an altered mannose trans-
port in CDGS ¢broblasts. Mannose enters CDGS
and control ¢broblasts using a speci¢c transport
mechanism. This transport is weakly inhibited by
phloridzin, a well known inhibitor of the glucose
Na-dependent transport family SGLT. Phloretin,
a potent inhibitor of the glucose facilitative trans-
porter family GLUT, inhibits mannose uptake in
both CDGS and control ¢broblasts. In the presence
of these two sugar transport inhibitors, the mannose
uptake in control and CDGS cells are very close. We
showed that D-[2-3H]-mannose transport is less sen-
sitive to competition with glucose than to competi-
tion with mannose in CDGS and control ¢broblasts.
Taken together, these results are in favor of the ex-
istence of the same speci¢c facilitative mannose
transporter in CDGS and control cells. However
qualitative and/or quantitative alterations are ob-
served in the kinetic parameters of mannose trans-
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port and the transport inhibition pro¢les. For exam-
ple, dMM which has been shown to inhibit the man-
nose uptake in a speci¢c manner [18] is less potent in
CDGS ¢broblasts than in control cells. The altera-
tions of mannose transport are noted when CDGS
¢broblasts are noted with control cells and when
CDGS subtypes are compared with each other.
The rate of D-[2-3H]-mannose uptake varies in a
large range in CDGS type I cells. In CDGS subtype
Ia, the mannose uptake is equivalent or higher than
in control cells. In a previous report, mannose up-
take was shown to be decreased in ¢broblasts derived
from two CDGS type I patients supposed to belong
to subtype Ia [10]. The ensemble of these observa-
tions indicates a large variability in mannose uptake
in subtype Ia CGDS. In CDGS Ib, we have found
the highest rate of mannose uptake whereas in
CDGS Ix, mannose uptake is identical to that ob-
served in control cells. With respect to modi¢cations
in the inhibition pro¢les of the mannose uptake, we
have found variations in the kinetic parameters of
mannose transport. By analogy with the glucose
transporter Glut-1, the high a⁄nity mannose trans-
porter may be a N-linked glycoprotein. It is well-
established that the glycan moiety of Glut-1 plays a
major role in glucose transport. The loss of the gly-
can chain of Glut-1 produces an increase in the
Kuptake for 2-deoxyglucose [23], on the contrary a
hyperglycosylation of the molecule decreases the
Kuptake value [24]. As CDGS is characterized by N-
glycosylation defects we cannot exclude that the gly-
cosylation pattern of the mannose transporter is
modi¢ed in CDGS derived ¢broblasts.
Mannose 6-phosphate is the precursor of mannose
1-phosphate and GDP-mannose via, respectively, the
PMM and GDP-mannose synthase. GDP-mannose
is the mannose donor in the glycoprotein glycan syn-
thesis. Mannose 6-phosphate can originate either
from fructose 6-phosphate, via PMI and the glucose
pathway, or from mannose phosphorylation by hex-
okinase. In CDGS subtype Ia with PMM de¢ciency,
both pathways are blocked but in subtype Ib with
PMI de¢ciency, the GDP-mannose can still be syn-
thesized from mannose. The synthesis of LLO is also
limited by the pool of free mannose in the cell. In-
terestingly we demonstrated in CDGS subtype Ib
¢broblasts, an increase in Vmax (higher number of
transporters) and a decrease in Kuptake (higher a⁄n-
ity) for the mannose speci¢c transporter. In this sub-
type, mannose enters easily the ¢broblasts and could
be used for LLO synthesis. These results are consis-
tent with the possible use of mannose as a therapeu-
tic agent in type Ib CDGS. Oral administration of
mannose is known to increase blood mannose levels
[25] which are lower in CDGS patients [26].
Although for the large majority of type Ia CDGS
patients, mannose therapy seems ine¡ective [27], our
results with CDGS Ix ¢broblasts suggest the possi-
bility of successful mannose therapy in patients with
type Ix CDGS.
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